Skip to main content
Premium Trial:

Request an Annual Quote

Insight Genetics Raises $3M in Private Offering

NEW YORK (GenomeWeb) – Insight Genetics has raised $3 million through a private securities offering, according to a filing with the US Securities and Exchange Commission.

According to the filing, the Nashville, Tennessee-based company had filed to sell up to $5 million in debt and options, warrants, or other rights to acquire another security.

Insight Genetics is developing molecular cancer diagnostics including PCR-based tests that identify ALK, ROS1, and RET fusions, as well as DEPDC1 overexpression, which have all been linked to various lung, breast, thyroid, and blood cancers.

Last year, the firm received a $1.3 million award from the National Cancer Institute to further develop an ALK test to monitor therapeutic resistance in non-small cell lung cancer patients. The company also inked a deal in January with Biocept to combine their respective technologies to enhance ALK expression and mutation detection in circulating tumor cells and tumor DNA.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.